Using an independent strategy, we identified Prkar1a in a genome‐wide screen as a tumor suppressor that collaborates with Trp53 haplo‐insufficiency and validated its action in mammary oncogenesis by direct in vivo genomic editing. Here, PRKAR1A is linked to neoplasm.